Free Trial
NASDAQ:IVF

INVO Fertility Q4 2025 Earnings Report

INVO Fertility logo
$1.59 -0.07 (-4.22%)
Closing price 04:00 PM Eastern
Extended Trading
$1.50 -0.09 (-5.35%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

INVO Fertility EPS Results

Actual EPS
$472.78
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

INVO Fertility Revenue Results

Actual Revenue
$1.60 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

INVO Fertility Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

INVO Fertility Earnings Headlines

Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.tc pixel
INVO Fertility Announces Fiscal Year 2025 Financial Results
INVO Fertility Discloses Delay In Quarterly Filing
See More INVO Fertility Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like INVO Fertility? Sign up for Earnings360's daily newsletter to receive timely earnings updates on INVO Fertility and other key companies, straight to your email.

About INVO Fertility

INVO Fertility (NASDAQ:IVF) (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation. By leveraging the natural conditions of the patient’s body, the INVOcell system aims to reduce the complexity, equipment requirements and cost associated with standard IVF lab procedures. INVO Fertility also provides complementary consumables and training programs to support fertility specialists in adopting its technology.

Originating in the early 2010s, INVO Fertility evolved from pioneering in-vivo fertilization research. The company secured U.S. Food and Drug Administration clearance for the INVOcell device in May 2015, marking a significant milestone that enabled commercial distribution. Since then, it has continued to expand its product portfolio and clinical support services to address the needs of fertility clinics and patients worldwide.

INVO Fertility markets and distributes its solutions across the United States and through a network of international partners in regions including Latin America, Europe, Asia-Pacific and the Middle East. The company collaborates with reproductive health professionals to provide hands-on training, technical assistance and ongoing clinical support, aiming to broaden access to cost-effective fertility treatment options globally.

View INVO Fertility Profile